Zeo ScientifiX, Inc. 8-K

What Happened

• On April 9, 2026 Zeo ScientifiX, Inc. (ZEOX) announced in a Form 8-K and press release that it entered into a memorandum of understanding (MOU) with Regen Therapy. The MOU establishes an exclusive scientific and biologics strategic collaboration and states that ZEO is expected to be positioned as the core supplier of advanced biologic therapeutics to be incorporated into Regen’s next‑generation regenerative offerings on its clinical platform. A copy of the press release was filed as Exhibit 99.1.

Key Details

• Filing date: April 9, 2026 (Form 8-K, Item 8.01; press release filed as Exhibit 99.1).
• Agreement type: Memorandum of understanding for an exclusive scientific and biologics strategic collaboration.
• Role: ZEO is described in the MOU as the expected core supplier of advanced biologic therapeutics for Regen’s clinical platform.
• Financial terms/timelines: The filing does not disclose financial terms, binding supply contracts, or detailed timelines.

Why It Matters

• The 8-K reports a strategic collaboration that formally links ZEO to Regen Therapy’s clinical platform and names ZEO as the expected core supplier of biologic therapeutics, signaling a potentially important commercial/scientific relationship. The filing contains no monetary commitments or definitive agreements; investors should watch for future disclosures that provide contractual terms, timelines, or revenue implications.